RiteMED Ciprofloxacin Indications/Uses

Treatment of the following infections caused by Ciprofloxacin-susceptible strains: Urinary tract infections: caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus epidermidis, Staphylococcus saprophyticus or Enterococcus faecalis.
Chronic Bacterial Prostatitis: caused by Escherichia coli or Proteus mirabilis.
Lower Respiratory Tract Infections: caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae or Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis.
Note: Although effective in clinical trials, Ciprofloxacin is NOT a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae.
Otitis Media: caused by Gram-negative organisms including Pseudomonas or by Staphylococcus.
Acute Sinusitis: caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis.
Skin and Skin Structure Infections: caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, Staphylococcus aureus (methicillin-susceptible), Staphylococcus epidermidis or Streptococcus pyogenes.
Bone and Joint Infections: caused by Enterobacter cloacae, Serratia marcescens or Pseudomonas aeruginosa.
Complicated Intra-Abdominal Infections (used in combination with metronidazole): caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae or Bacteroides fragilis.
Infectious Diarrhea: caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii, Shigella dysenteriae, Shigella flexneri or Shigella sonnei when antibacterial therapy is indicated.
Typhoid Fever (Enteric Fever): caused by Salmonella typhi.
Note: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated.
Uncomplicated cervical and urethral gonorrhea: due to Neisseria gonorrhoeae.
Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis.
Perform appropriate culture and susceptibility tests before treatment in order to isolate and identify organisms causing infection and to determine susceptibility to ciprofloxacin. Therapy with Ciprofloxacin may be initiated before results of these tests are known. Institute appropriate therapy once results become available. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.